StockNasdaqGSVRTX
Vertex Pharmaceuticals
$522.38
+4.78 (+0.92%)today
Valuation & earnings
- P/E ratio
- 30.39
- Forward P/E
- 26
- EPS (ttm)
- $17.19
- Forward EPS
- $20.09
- Price/book
- 6.54
- PEG ratio
- 1.9
- Payout ratio
- 0%
Financials (ttm)
- Revenue (ttm)
- 12.6B
- Revenue growth
- 12.5%
- Profit margin
- 35%
- Return on equity
- 23.54%
- Total cash
- 7.9B
- Total debt
- 2B
Earnings (EPS)
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Sep 30, 2025 | 4.58 | 4.8 | +4.87% |
| Dec 31, 2025 | 5.15 | 5.03 | -2.3% |
| Mar 31, 2026 | 4.31 | 4.47 | +3.81% |
| Jun 30, 2026 | 4.75 | 4.73 | -0.32% |
Next earnings date: Nov 2, 2026
Analyst view
Consensus ratingBuy32 analysts
Strong buy 6Buy 20Hold 4Sell 1Strong sell 1
12-month price targetsImplied upside: +9.18%
350
570.32
672
LowCurrent priceHigh
Latest news
(English)Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
ZacksSep 24, 2026
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
ZacksSep 24, 2026
Lilly’s latest China drug deal; Immunovant’s setback in lupus
BioPharma DiveSep 24, 2026
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Motley FoolSep 24, 2026
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
Simply Wall St.Sep 24, 2026
Vertex Posts Positive Phase II Data on Kidney Disease Drug
ZacksSep 23, 2026
Related products
How visible is Vertex Pharmaceuticals in AI search?
We ask AI search engines about Vertex Pharmaceuticals and its market — live — and measure whether and how prominently the brand appears in their answers.
No AI visibility check has been run for Vertex Pharmaceuticals yet.
Run a live check to see how AI search engines talk about this brand right now.
Is your brand this visible in AI search?
Aurora tracks your brand across 7 AI search engines — visibility, share of voice and the sources that shape AI answers.